PMID- 8848466
OWN - NLM
STAT- MEDLINE
DCOM- 19961024
LR  - 20191210
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 53
IP  - 1
DP  - 1996 Jan
TI  - Reinforcing effects of certain serotonin-releasing amphetamine derivatives.
PG  - 99-105
AB  - The present study was designed to characterize further the rewarding and aversive 
      properties of 3,4-methylenedioxymethamphetamine (MDMA), the alpha-ethyl homologue 
      of MDMA (MBDB), fenfluramine, and the selective serotonin releasing agent 
      5-methoxy-6-methyl-2-aminoindan (MMAI) using the conditioned place preference 
      paradigm (CPP). Extracellular dopamine (DA) and its metabolite DOPAC were also 
      measured in the nucleus accumbens after systemic drug administration, using in 
      vivo microdialysis in freely moving rats. MDMA produced a positive dose-dependent 
      effect in the CPP test, which was maximal at doses of 5 and 10 mg/kg. MBDB also 
      induced a positive CPP, with a maximum effect at 10 mg/kg. The conditioning 
      effect of MBDB was more than 2.5-fold weaker compared with MDMA. Fenfluramine 
      evoked place aversion at doses of 4, 6, and 10 mg/kg. This effect of fenfluramine 
      was independent of dose. MMAI at doses of 1.25, 2.5, and 5 mg/kg produced no 
      significant effect on place conditioning. At doses of 10 and 20 mg/kg, MMAI 
      produced an effect similar to fenfluramine: Place aversion was independent of 
      dose. In the microdialysis experiments, MDMA significantly elevated extracellular 
      DA and induced a decrease of DOPAC in the nucleus accumbens. Thus, activation of 
      dopaminergic systems may be responsible for the rewarding properties of MDMA-like 
      drugs. In contrast to the effects seen with MDMA, no difference in extracellular 
      DA or DOPAC was seen after injection of MBDB, fenfluramine, or MMAI, even though 
      MBDB weakly induced a place preference. The mechanism responsible for the 
      development of place aversion by fenfluramine or MMAI is unknown at this time and 
      requires further study.
FAU - Marona-Lewicka, D
AU  - Marona-Lewicka D
AD  - Department of Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
FAU - Rhee, G S
AU  - Rhee GS
FAU - Sprague, J E
AU  - Sprague JE
FAU - Nichols, D E
AU  - Nichols DE
LA  - eng
GR  - DA-04758/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Amphetamines)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Indans)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 132980-16-6 (5-methoxy-6-methyl-2-aminoindan)
RN  - 2DS058H2CF (Fenfluramine)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Conditioning, Operant/*drug effects
MH  - Dopamine/metabolism
MH  - Dopamine Antagonists/pharmacology
MH  - Fenfluramine/pharmacology
MH  - Indans/pharmacology
MH  - Male
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Rats
MH  - Reinforcement, Psychology
MH  - Serotonin/*metabolism
MH  - Serotonin Agents/pharmacology
MH  - Serotonin Receptor Agonists/*pharmacology
MH  - Synaptic Transmission/drug effects
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 0091-3057(95)00205-7 [pii]
AID - 10.1016/0091-3057(95)00205-7 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 1996 Jan;53(1):99-105. doi: 
      10.1016/0091-3057(95)00205-7.